Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGT ((VSE:IGT) Blockbuster Anti-Cancer Test Results !!! -- Ignore unavailable to you. Want to Upgrade?

To: Spiney who wrote (83)	5/30/2000 1:44:00 PM
From: Spiney	Read Replies (1) \| Respond to of 94

News!!! I missed the mark...but I'll take it! IGT Pharma animal study results encouraging IGT Pharma has received results from a recent animal study that may lead to new hope for stroke victims. Conducted under contract at the National Research Council, the results demonstrate that IGT440103 provided significant protection to living brain cells subjected to the conditions of stroke. In direct comparison with the accepted research standard, IGT440103 was up to 30 times more potent in achieving equivalent therapeutic results. Stroke is the third leading cause of death in North America where 50 per cent of victims are left with long-term disabilities, Dr. Kenneth Curry, IGT's chief scientific officer, states: "Stroke occurs when normal blood supply to a portion of the brain is interrupted. About 80 per cent of strokes are caused by blood clots." Dr. Curry went on to say: "Available treatments can be used safely by only 5 per cent of stroke victims. Furthermore, the treatment falls short by only attempting to dissolve the clots in order to re-establish blood supply. IGT440103 appears unique in its ability to minimize the brain damage which occurs after the stroke." The estimated market size for stroke drugs could exceed several billion dollars per year. This new drug is the first in a series of novel amino acid derivatives that IGT has designed to act specifically in the brain. This is accomplished by targeting a recently discovered receptor system, the mGluRs (metabotrople glutamate receptors), that modulate and balance brain function. The advantage of this strategy is that IGT is capable of designing highly potent drugs that interact only with the mGluRs, thus eliminating the side effects associated with many currently used neurological drugs. IGT is acknowledged as a world leader in the discovery of drugs that target the mGluR system. Building on these recent results, IGT will embark on a comprehensive study to further confirm and expand on the therapeutic potential of IGT440103 for the treatment of stroke and other brain diseases. IGT currently has six other patented drug concepts under investigation relating to conditions such as anxiety, schizophrenia, epilepsy and drug dependence.